Humacyte (NASDAQ:HUMA) Announces Earnings Results, Hits Expectations

Humacyte (NASDAQ:HUMA) posted its earnings results on Friday. The company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13), FiscalAI reports. The firm had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million.

Here are the key takeaways from Humacyte’s conference call:

• Commercial launch momentum for Symvess — 27 VAC approvals to date, 43 VAC reviews pending, 27 hospitals have ordered (most reordering), and the price cut to $17,000 has raised VAC success to ~70% and increased repeat usage.
• First-of-its-kind U.S. Department of Defense funding has been allocated for procurement and training of biologic vascular repair technologies, which could drive meaningful adoption and non‑commercial volume in 2026.
• Dialysis access is a near-term regulatory catalyst: positive V007 two‑year results support ATEV, the V012 interim analysis (first 80 patients to one year) will report by early June 2026, and Humacyte plans a supplemental BLA submission in H2 2026 if results are supportive.
• Financial mix is mixed — Q4 net loss widened to $24.8M largely due to an $8.9M inventory reserve and unused capacity costs, but FY25 net loss improved to $40.8M year-over-year and liquidity was bolstered by ~$50M cash at year‑end plus subsequent equity raises and a $40M initial tranche of a $77.5M credit facility.
• Pipeline progress beyond trauma — the CTEV coronary graft completed positive preclinical work, an IND was submitted and commercial-scale manufacturing started, targeting first‑in‑human coronary trials in H2 2026.

Humacyte Price Performance

Shares of NASDAQ HUMA traded down $0.07 during midday trading on Friday, reaching $0.71. The stock had a trading volume of 7,051,257 shares, compared to its average volume of 6,658,179. The stock has a 50-day moving average of $1.05 and a 200-day moving average of $1.29. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. The company has a market capitalization of $132.21 million, a price-to-earnings ratio of -3.08 and a beta of 1.89. Humacyte has a 12-month low of $0.70 and a 12-month high of $2.93.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its stake in Humacyte by 41.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 45,960 shares of the company’s stock worth $96,000 after buying an additional 13,407 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Humacyte during the fourth quarter valued at about $82,000. Price T Rowe Associates Inc. MD lifted its position in shares of Humacyte by 21.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 76,017 shares of the company’s stock valued at $73,000 after acquiring an additional 13,175 shares in the last quarter. Kovack Advisors Inc. purchased a new position in shares of Humacyte in the fourth quarter valued at about $70,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Humacyte in the third quarter worth about $46,000. Institutional investors own 44.71% of the company’s stock.

Wall Street Analysts Forecast Growth

HUMA has been the subject of several research reports. BTIG Research reduced their price target on shares of Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Friday. HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of Humacyte in a research report on Monday, December 1st. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a research report on Sunday, December 21st. UBS Group reiterated a “buy” rating on shares of Humacyte in a research note on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Humacyte has a consensus rating of “Moderate Buy” and a consensus price target of $7.71.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.